Eagle Pharmaceuticals Analyst Ratings
Eagle Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | -15.34% | Piper Sandler | $26 → $17 | Downgrades | Neutral → Underweight |
| 03/02/2020 | 129.08% | Cantor Fitzgerald | $58 → $46 | Maintains | Neutral |
| 03/22/2019 | 104.18% | Mizuho | $40 → $41 | Maintains | Neutral |
| 10/31/2018 | 168.92% | Piper Sandler | $82 → $54 | Downgrades | Overweight → Neutral |
| 09/21/2018 | 298.41% | Cantor Fitzgerald | $81 → $80 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | -15.34% | 派珀·桑德勒 | $26→$17 | 評級下調 | 中性→減持 |
| 03/02/2020 | 129.08% | 康託·菲茨傑拉德 | $58→$46 | 維護 | 中性 |
| 2019/03/22 | 104.18% | 瑞穗 | $40→$41 | 維護 | 中性 |
| 2018年10月31日 | 168.92% | 派珀·桑德勒 | $82→$54 | 評級下調 | 超重→中性 |
| 2018年09月21日 | 298.41% | 康託·菲茨傑拉德 | $81→$80 | 維護 | 超重 |
What is the target price for Eagle Pharmaceuticals (EGRX)?
Eagle PharmPharmticals(EGRX)的目標價是多少？
The latest price target for Eagle Pharmaceuticals (NASDAQ: EGRX) was reported by Piper Sandler on August 9, 2023. The analyst firm set a price target for $17.00 expecting EGRX to fall to within 12 months (a possible -15.34% downside). 1 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年8月9日報道了鷹製藥(納斯達克代碼：EGRX)的最新目標價。這家分析公司將目標價定為17.00美元，預計EGRX將在12個月內降至(可能下跌15.34%)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Eagle Pharmaceuticals (EGRX)?
分析師對鷹製藥(Eagle PharmPharmticals)的最新評級是多少？
The latest analyst rating for Eagle Pharmaceuticals (NASDAQ: EGRX) was provided by Piper Sandler, and Eagle Pharmaceuticals downgraded their underweight rating.
分析師對鷹製藥(納斯達克代碼：EGRX)的最新評級由Piper Sandler提供，鷹製藥下調了其減持評級。
When is the next analyst rating going to be posted or updated for Eagle Pharmaceuticals (EGRX)?
Eagle PharmPharmticals(EGRX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eagle Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eagle Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Eagle PharmPharmticals的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Eagle PharmPharmticals的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating Eagle Pharmaceuticals (EGRX) correct?
分析師對Eagle PharmPharmticals(EGRX)的評級正確嗎？
While ratings are subjective and will change, the latest Eagle Pharmaceuticals (EGRX) rating was a downgraded with a price target of $26.00 to $17.00. The current price Eagle Pharmaceuticals (EGRX) is trading at is $20.08, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Eagle PharmPharmticals(EGRX)評級為下調，目標價為26.00美元至17.00美元。Eagle PharmPharmticals(EGRX)目前的股價為20.08美元，超出了分析師的預測區間。